Compare MS & AZN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MS | AZN |
|---|---|---|
| Founded | 1924 | 1992 |
| Country | United States | United Kingdom |
| Employees | 83000 | 96100 |
| Industry | Investment Bankers/Brokers/Service | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 255.2B | 311.3B |
| IPO Year | N/A | N/A |
| Metric | MS | AZN |
|---|---|---|
| Price | $165.91 | $203.14 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 15 | 1 |
| Target Price | ★ $178.00 | N/A |
| AVG Volume (30 Days) | ★ 5.6M | 1.7M |
| Earning Date | 04-15-2026 | 04-28-2026 |
| Dividend Yield | ★ 2.41% | 1.59% |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $12.09 | $10.13 |
| Revenue Next Year | $5.39 | $6.21 |
| P/E Ratio | ★ $17.30 | $31.91 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $94.33 | $61.24 |
| 52 Week High | $192.68 | $212.71 |
| Indicator | MS | AZN |
|---|---|---|
| Relative Strength Index (RSI) | 51.99 | 66.95 |
| Support Level | $154.82 | $182.39 |
| Resistance Level | $165.96 | $211.32 |
| Average True Range (ATR) | 4.59 | 3.50 |
| MACD | 1.19 | 0.28 |
| Stochastic Oscillator | 73.93 | 92.48 |
Morgan Stanley is a massive global financial services firm, with offices in 42 countries and more than 82,000 employees as of year-end 2025. The firm cut its teeth in investment banking and institutional trading, where it maintains a strong presence today, but generates the lion share of its income from wealth and asset management franchises, where it boasted $9.3 trillion in client assets at the end of its most recent fiscal year. After reincorporation as a bank holding company in the wake of the global financial crisis, Morgan Stanley also boasts a top 10 banking franchise by deposits, with more than $400 billion in customer deposits, predominately attributable to cash sweeps from its wealth management and brokerage businesses.
A merger between Astra of Sweden and Zeneca of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across a number of major therapeutic areas, including oncology (over 40% of total revenue), cardiovascular, renal, and metabolic (over 20%), rare disease (16%), and respiratory and immunology (15%). The majority of sales comes from international markets, with the United States representing close to one-third of its sales.